Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis

Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis

Thumbnail Image
Download
Name

Lander_Genomic analysis.pdf

Size

1.32 MB

Format

Adobe PDF

Checksum (MD5)

ecc22324586afbaa4b3d3a90596a857e

Author(s)
Farhat, Maha R.
•
Shapiro, B. Jesse
•
Kieser, Karen J.
•
Sultana, Razvan
•
Jacobson, Karen R.
•
Victor, Thomas C.
•
Warren, Robin M.
•
Streicher, Elizabeth M.
•
Calver, Alistair
•
Sloutsky, Alex
more
Date Issued
September 2013
Journal
Nature Genetics
Publisher
Nature Publishing Group
Citation
Farhat, Maha R, B Jesse Shapiro, Karen J Kieser, Razvan Sultana, Karen R Jacobson, Thomas C Victor, Robin M Warren, et al. “Genomic Analysis Identifies Targets of Convergent Positive Selection in Drug-Resistant Mycobacterium Tuberculosis.” Nature Genetics 45, no. 10 (September 1, 2013): 1183–1189.
Version
Author's final manuscript
Abstract
M. tuberculosis is evolving antibiotic resistance, threatening attempts at tuberculosis epidemic control. Mechanisms of resistance, including genetic changes favored by selection in resistant isolates, are incompletely understood. Using 116 newly sequenced and 7 previously sequenced M. tuberculosis whole genomes, we identified genome-wide signatures of positive selection specific to the 47 drug-resistant strains. By searching for convergent evolution—the independent fixation of mutations in the same nucleotide position or gene—we recovered 100% of a set of known resistance markers. We also found evidence of positive selection in an additional 39 genomic regions in resistant isolates. These regions encode components in cell wall biosynthesis, transcriptional regulation and DNA repair pathways. Mutations in these regions could directly confer resistance or compensate for fitness costs associated with resistance. Functional genetic analysis of mutations in one gene, ponA1, demonstrated an in vitro growth advantage in the presence of the drug rifampicin.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
http://creativecommons.org/licenses/by-nc-sa/4.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/86358
DOI of Published Version
https://doi.org/10.1038/ng.2747
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.